+

WO2007047575A3 - Traitements pharmacologiques contre des troubles du sommeil - Google Patents

Traitements pharmacologiques contre des troubles du sommeil Download PDF

Info

Publication number
WO2007047575A3
WO2007047575A3 PCT/US2006/040362 US2006040362W WO2007047575A3 WO 2007047575 A3 WO2007047575 A3 WO 2007047575A3 US 2006040362 W US2006040362 W US 2006040362W WO 2007047575 A3 WO2007047575 A3 WO 2007047575A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
vanilloid
sleep
breathing disorders
related breathing
Prior art date
Application number
PCT/US2006/040362
Other languages
English (en)
Other versions
WO2007047575A2 (fr
Inventor
David W Carley
Miodrag Radulovacki
Original Assignee
Univ Illinois
David W Carley
Miodrag Radulovacki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, David W Carley, Miodrag Radulovacki filed Critical Univ Illinois
Publication of WO2007047575A2 publication Critical patent/WO2007047575A2/fr
Publication of WO2007047575A3 publication Critical patent/WO2007047575A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes pour prévenir ou améliorer des troubles de la respiration associés au sommeil. La méthode consiste à administrer à un patient une dose efficace d'un ligand ou d'une combinaison de ligands du récepteur vanilloïde. Le ligand ou la combinaison de ligands du récepteur vanilloïde peuvent être administrés en conjonction avec un ou plusieurs agonistes du récepteur de sérotonine, un ou plusieurs agents cannabimimétiques, un ou plusieurs inhibiteurs de recaptage de sérotonine, un ou plusieurs inhibiteurs de recaptage de noradrénaline, une combinaison d'inhibiteurs de recaptage, un ou plusieurs inhibiteurs de synthèse ou de libération de vanilloïde ou une combinaison quelconque de ces substances.
PCT/US2006/040362 2005-10-14 2006-10-13 Traitements pharmacologiques contre des troubles du sommeil WO2007047575A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72670805P 2005-10-14 2005-10-14
US60/726,708 2005-10-14

Publications (2)

Publication Number Publication Date
WO2007047575A2 WO2007047575A2 (fr) 2007-04-26
WO2007047575A3 true WO2007047575A3 (fr) 2007-07-12

Family

ID=37762448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040362 WO2007047575A2 (fr) 2005-10-14 2006-10-13 Traitements pharmacologiques contre des troubles du sommeil

Country Status (1)

Country Link
WO (1) WO2007047575A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2408434A4 (fr) * 2009-03-16 2013-11-27 Ipintl Llc Traitement de la maladie d'alzheimer et de l'ostéoporose, et réduction du vieillissement
KR102587297B1 (ko) * 2017-08-31 2023-10-12 (주)아모레퍼시픽 수면장애 예방 또는 치료용 조성물
KR102587300B1 (ko) 2017-08-31 2023-10-12 (주)아모레퍼시픽 아토피피부염 예방 또는 치료용 조성물
WO2024124172A1 (fr) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions et procédés pour stimuler et/ou améliorer la motivation d'exercice et/ou les performances physiques

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016318A1 (fr) * 2000-08-21 2002-02-28 Pacific Corporation Nouveaux derives de thiourea et compositions pharmaceutiques renfermant ceux-ci
WO2002080903A1 (fr) * 2001-04-06 2002-10-17 The Board Of Trustees Of The University Of Illinois Role fonctionnel des cannabinoides sur la stabilite autonome pendant le sommeil
WO2003027064A1 (fr) * 2001-09-27 2003-04-03 Digital Biotech Co. Ltd,. Analogues simplifies de resiniferatoxine utilises en tant qu'agonistes des recepteurs vanilloide presentant une excellente activite analgesique, et compositions pharmaceutiques contenant ces analogues
WO2003080036A2 (fr) * 2002-03-25 2003-10-02 Lmd Utilisation d'un vanilloide comme anti-ronflement
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
WO2006133197A1 (fr) * 2005-06-06 2006-12-14 The Board Of Trustees Of The University Of Illinois Compositions et methodes servant a traiter les troubles du sommeil

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016318A1 (fr) * 2000-08-21 2002-02-28 Pacific Corporation Nouveaux derives de thiourea et compositions pharmaceutiques renfermant ceux-ci
WO2002080903A1 (fr) * 2001-04-06 2002-10-17 The Board Of Trustees Of The University Of Illinois Role fonctionnel des cannabinoides sur la stabilite autonome pendant le sommeil
WO2003027064A1 (fr) * 2001-09-27 2003-04-03 Digital Biotech Co. Ltd,. Analogues simplifies de resiniferatoxine utilises en tant qu'agonistes des recepteurs vanilloide presentant une excellente activite analgesique, et compositions pharmaceutiques contenant ces analogues
WO2003080036A2 (fr) * 2002-03-25 2003-10-02 Lmd Utilisation d'un vanilloide comme anti-ronflement
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
WO2006133197A1 (fr) * 2005-06-06 2006-12-14 The Board Of Trustees Of The University Of Illinois Compositions et methodes servant a traiter les troubles du sommeil

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
APPENDINO G ET AL: "TRPV1 (VANILLOID RECEPTOR, CAPSAICIN RECEPTOR) AGONISTS AND ANTAGONISTS", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 13, no. 12, 2003, pages 1825 - 1837, XP002320750, ISSN: 1354-3776 *
CARLEY D W ET AL: "C-fiber activation exacerbates sleep-disordered breathing in rats.", SLEEP & BREATHING = SCHLAF & ATMUNG SEP 2004, vol. 8, no. 3, September 2004 (2004-09-01), pages 147 - 154, XP002423253, ISSN: 1520-9512 *
GERAGHTY DOMINIC P ET AL: "RESPIRATORY ACTIONS OF VANILLOID RECEPTOR AGONISTS IN THE NUCLEUS OF THE SOLITARY TRACT: COMPARISON OF RESINIFERATOXIN WITH NON-PUNGENT AGENTS AND ANANDAMIDE", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 137, no. 6, 2002, pages 919 - 927, XP008075862, ISSN: 0007-1188 *
SABOGAL CARLOS ET AL: "PROTECTIVE EFFECT OF PALIVIZUMAB AGAINST CAPSAICIN-INDUCED APNEA/HYPOPNEA IN RESPIRATORY SYNCYTIAL VIRUS (RSV)-INFECTED F-344 RATS", PEDIATRIC RESEARCH, WILLIAMS AND WILKINS, BALTIMORE, MD,, US, vol. 51, no. 4 PT 2, April 2002 (2002-04-01), pages 395A, XP008075769, ISSN: 0031-3998 *
SZALLASI A: "VANILLOID RECEPTOR LIGANDS HOPES AND REALITIES FOR THE FUTURE", DRUGS AND AGING, ADIS INTERNATIONAL LTD, NZ, vol. 18, no. 8, 2001, pages 561 - 573, XP001105341, ISSN: 1170-229X *

Also Published As

Publication number Publication date
WO2007047575A2 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2007047372A3 (fr) Traitements pharmacologiques contre des troubles du sommeil
JP2010535252A5 (fr)
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
JP2007521835A5 (fr)
UA98136C2 (ru) Применение аклидиния для лечения респираторных заболеваний
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2009013989A (es) Terapia en combinacion para depresion.
HK1104471A1 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
WO2010015260A3 (fr) Administration par infusion pour le traitement d’effets ischémiques
WO2009127974A3 (fr) Préparation pharmaceutique pour le traitement de maladies cardiovasculaires
NO20080936L (no) Transdermale medikamentleveringsinnretninger inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
Ayatollahi et al. Effect of intravenous vitamin C on postoperative pain in uvulopalatopharyngoplasty with tonsillectomy
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
NO20052420L (no) Farmakologisk behandling av sovnapn±.
WO2007105113A3 (fr) Application des antagonistes du récepteur crf1 à l'élaboration d'un médicament destiné au traitement du syndrome métabolique et/ou de l'obésité et/ou d'une dyslipoprotéinémie
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX2009011900A (es) Curacion de herida diabetica.
WO2007047575A3 (fr) Traitements pharmacologiques contre des troubles du sommeil
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
WO2007133796A3 (fr) Procédés et compositions de traitement de l'apnée du sommeil
WO2008032222A3 (fr) Traitement des vertiges avec de l'acétyl-l-leucine
DK1715859T3 (da) Fremgangsmåde til behandling og diagnosticering af åndedrætsforstyrrelser i sövnen ved hjælp af zonisamid og midler til at gennemföre fremgangsmåden
Tuncer et al. The pre‐emptive analgesic effect of intra‐articular bupivacaine in arthroscopic knee surgery
WO2007035879A3 (fr) Combinaison de produits pharmaceutiques a base de s-nitrosothiol pour retablir un rythme respiratoire normal
JP2014534229A5 (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06816989

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载